Chemical amplification based on fluid partitioning

A system for nucleic acid amplification of a sample comprises partitioning the sample into partitioned sections and performing PCR on the partitioned sections of the sample. Another embodiment of the invention provides a system for nucleic acid amplification and detection of a sample comprising partitioning the sample into partitioned sections, performing PCR on the partitioned sections of the sample, and detecting and analyzing the partitioned sections of the sample.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

More than one reissue application has been filed for the reissue of U.S. Pat. No. 7,041,481, the reissue applications are application Ser. No. 16/115,187, filed Aug. 28, 2018, which is a continuation reissue application of reissue of application Ser. No. 15/421,141, filed Jan. 31, 2017, now U.S. Pat. No. Re. RE47,080, issued Oct. 8, 2018, which is a continuation reissue application of reissue application Ser. No. 14/701,392, filed Apr. 30, 2015, now U.S. Pat. No. Re. RE46,322, issued Feb. 28, 2017, which is a continuation reissue application of application Ser. No. 13/436,693, filed Mar. 30, 2012, now U.S. Pat. No. Re. 45,539, issued Jun. 2, 2015 which is a continuation reissue application of application Ser. No. 12/891,733, filed Sep. 27, 2010, issued as U.S. Pat. No. Re. 43,365, which is a continuation reissue application of reissue application Ser. No. 12/118,418, filed May 9, 2008, issued as U.S. Pat. No. Re. 41,780, which is a reissue application of U.S. Pat. No. 7,041,481. The present application is a Reissue of application Ser. No. 10/389,130, filed Mar. 14, 2003, issued as U.S. Pat. No. 7,041,481 on May 9, 2006 and adds new claims relative to U.S. Pat. No. 7,041,481.

The United States Government has rights in this invention pursuant to Contract No. W-7405-ENG-48 between the United States Department of Energy and the University of California for the operation of Lawrence Livermore National Laboratory. This invention was made with government support under W-7405-ENG-48 awarded by United States Department of Energy. The government has certain rights in the invention.

BACKGROUND

1. Field of Endeavor

The present invention relates to chemical amplification and more particularly to chemical amplification based on fluid partitioning.

2. State of Technology

U.S. Pat. No. 4,683,202 issued Jul. 28, 1987; U.S. Pat. No. 4,683,195 issued Jul. 28, 1987; and U.S. Pat. No. 4,800,159 issued Jan. 24, 1989 to Kary B. Mullis et al provide background information. The patents describe processes for producing any particular nucleic acid sequence from a given sequence of DNA or RNA in amounts which are large compared to the amount initially present. The DNA or RNA may be single-or-double-stranded, and may be a relatively pure species or a component of a mixture of nucleic acids. The process utilizes a repetitive reaction to accomplish the amplification of the desired nucleic acid sequence. The extension product of one primer when hybridized to the other becomes a template for the production of the desired specific nucleic acid sequence, and vice versa, and the process is repeated as often as is necessary to produce the desired amount of the sequence.

U.S. Pat. No. 6,503,715 for a nucleic acid ligand diagnostic biochip issued Jan. 7, 2003 provides the following background information, “Methods are provided in the instant invention for obtaining diagnostic and prognostic Nucleic acid ligands, attaching said ligands to a Biochip, and detecting binding of target molecules in a Bodily to said Biochip-bound Nucleic acid ligands.” In one embodiment of the instant invention, one or more Nucleic acid ligands are chosen that bind to molecules known to be diagnostic or prognostic of a disease; these ligands are then attached to the Biochip. Particular methods for attaching the Nucleic acid ligands to the Biochip are described below in the section entitled “Fabrication of the Nucleic Acid Biochip.” The Biochip may comprise either (i) Nucleic acid ligands selected against a single target molecule; or more preferably, (ii) Nucleic acid ligands selected against multiple target molecules.

U.S. Patent Application No. 2002/0197623 for nucleic acid detection assays published Dec. 26, 2002 provides the following background information, “means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences . . . methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.”

SUMMARY

Features and advantages of the present invention will become apparent from the following description. Applicants are providing this description, which includes drawings and examples of specific embodiments, to give a broad representation of the invention. Various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this description and by practice of the invention. The scope of the invention is not intended to be limited to the particular forms disclosed and the invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.

The present invention provides an apparatus for nucleic acid amplification of a sample comprising means for partitioning the sample into partitioned sections and means for performing PCR on the partitioned sections of the sample. Another embodiment of the invention provides an apparatus for nucleic acid amplification and detection of a sample comprising means for partitioning the sample into partitioned sections, means for performing PCR on the partitioned sections of the sample, and means for detection and analysis of the partitioned sections of the sample. The present invention also provides a method of nucleic acid amplification of a sample comprising the steps of partitioning the sample into partitioned sections and subjecting the partitioned sections of the sample to PCR. Another embodiment of a method of the present invention provides a method of nucleic acid amplification and detection of a sample comprising the steps of partitioning the sample into partitioned sections, subjecting the partitioned sections of the sample to PCR, and detecting and analyzing the partitioned sections of the sample.

The invention is susceptible to modifications and alternative forms. Specific embodiments are shown by way of example. It is to be understood that the invention is not limited to the particular forms disclosed. The invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated into and constitute a part of the specification, illustrate specific embodiments of the invention and, together with the general description of the invention given above, and the detailed description of the specific embodiments, serve to explain the principles of the invention.

FIG. 1 is a flow diagram illustrating one embodiment of a system constructed in accordance with the present invention.

FIG. 2 is a flow diagram illustrating another embodiment of a system constructed in accordance with the present invention.

FIG. 3 is a diagram of another embodiment of a system constructed in accordance with the present invention.

FIG. 4 is a diagram of another embodiment of a system constructed in accordance with the present invention.

FIG. 5 is a diagram of another embodiment of a system constructed in accordance with the present invention.

 DETAILED DESCRIPTION OF THE INVENTION

Referring now to the drawings, to the following detailed description, and to incorporated materials; detailed information about the invention is provided including the description of specific embodiments. The detailed description serves to explain the principles of the invention. The invention is susceptible to modifications and alternative forms. The invention is not limited to the particular forms disclosed. The invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.

Referring now to the drawings, and in particular to FIG. 1, a flow diagram of one embodiment of a system constructed in accordance with the present invention is illustrated. The system is designated generally by the reference numeral 100. The system 100 provides a method and apparatus for performing extremely rapid nucleic acid amplification. The flow diagram illustrating system 100 shows block 101 “partitioning” the sample and block 102 performing “CR” on the sample. The system 100 provides an apparatus for nucleic acid amplification of a sample comprising means for partitioning the sample and means for performing PCR on the sample. The system 100 also provides a method of nucleic acid amplification of a sample comprising the steps of partitioning the sample and subjecting the sample to PCR. The system 100 has application wherever current PCR-type systems exist.

In block 101 a chemical reagent and an input sample are “partitioned” into a large number of microdroplets or other forms of fluid partitions prior to amplification in block 102. The partitioning 101 involves dispersing the DNA-containing solution. For example the partitioning 101 can be accomplished by dispersing the DNA-containing solution in an immiscible carrier liquid. The DNA-containing solution is dispersed in the immiscible carrier fluid as microdroplets. The DNA-containing solution can be partitioned in other ways, for example, by being dispersed as liquid slugs separated by the carrier fluid, as an emulsion with the carrier fluid, or by using a gelling agent that prevents transfer of DNA between partitioned regions. The DNA-containing solution can also be partitioned mechanically by partitioning the fluid into micro-tubes or capillaries, or into micro-wells.

With the system 100, each partitioned DNA-containing fluid volume contains the necessary biochemical constituents for selectively amplifying a specified portion of a sample DNA via polymerase chain reaction (PCR). The target DNA can be detected by monitoring for the colorimetric indicator (e.g., flourescence or optical absorption) generated with each DNA template duplicaton sequence.

In block 102 selected portions of each nucleic acid sample are amplified using polymerase chain reaction (PCR), with the product contained in each partitioned fluid volume. This results in much more concentrated amplification product, since the volume containing the reaction is so small.

The polymerase chain reaction (PCR), is a cyclic process whereby a large quantity of identical DNA strands can be produced from one original template. The procedure was developed in 1985 by Kerry Mullis, who was awarded the 1993 Nobel prize in chemistry for his work. In PCR, DNA is immersed in a solution containing the enzyme DNA polymerase, unattached nucleotide bases, and primers, which are short sequences of nucleotides designed to bind with an end of the desired DNA segment. Two primers are used in the process: one primer binds at one end of the desired segment on one of the two paired DNA strands, and the other primer binds at the opposite end on the other strand. The solution is heated to break the bonds between the strands of the DNA, then when the solution cools, the primers bind to the separated strands, and DNA polymerase quickly builds a new strand by joining the free nucleotide bases to the primers in the 5′-3′ direction. When this process is repeated, a strand that was formed with one primer binds to the other primer, resulting in a new strand that is restricted solely to the desired segment. Thus the region of DNA between the primers is selectively replicated. Further repetitions of the process can produce a geometric increase in the number of copies, (theoretically 2n if 100% efficient whereby n equals the number of cycles), in effect billions of copies of a small piece of DNA can be replicated in several hours.

A PCR reaction is comprised of (a) a double-stranded DNA molecule, which is the “template” that contains the sequence to be amplified, (b) primer(s), which is a single-stranded DNA molecule that can anneal (bind) to a complimentary DNA sequence in the template DNA; (c) dNTPs, which is a mixture of dATP, dTTP, dGTP, and dCTP which are the nucleotide subunits that will be put together to form new DNA molecules in the PCR amplification procedure; and (d) Taq DNA polymerase, the enzyme which synthesizes the new DNA molecules using dNTPs.

Current amplification systems are limited in practice to half hour type amplification and detection windows (−30 cycles, 1 minute/cycle). The system 100 provides faster amplification. This has many applications, for example, in Homeland Defense applications, faster detection methods (a few minutes) can push the deployment of these sensors from “detect to treat” to “detect to protect,” having a serious impact on the number of casualties from a massive bioagent release.

The system 100 has significant advantages over typical bulk DNA detection techniques (even microscale bulk solution approaches), including (1) much faster detection time through a reduction in the total number of temperature cycles required, (2) a reduction in the time for each cycle, and (3) removing interference from competing DNA templates. The system 100 achieves a reduction in the total number of cycles by limiting the dilution of the optically generated signal (e.g., fluorescence or absorption). The formation of partitioned fluid volumes of the DNA-containing solution effectively isolates the fluid volumes which contain the target DNA from the fluid volumes that do not contain the target DNA. Therefore, the dilution of the optical signal is largely eliminated, allowing much earlier detection. This effect is directly related to the number of fluid partitions formed from the initial sample/reagent pool.

The system 100 achieves a reduction in the total number of cycles that are needed by limiting the dilution of the optically generated signal (e.g., fluorescence or absorption). The formation of partitioned fluid volumes of the DNA-containing solution effectively isolates the fluid volumes which contain the target DNA from the fluid volumes that do not contain the target DNA. Therefore, the dilution of the optical signal is largely eliminated, allowing much earlier detection. This effect is directly related to the number of fluid partitions formed from the initial sample/reagent pool. The effect of the number of fluid partitions on the number of cycles required for detection can be described by the following Equation E1:

N = ln ⁢ ⁢ D L ⁢ A N ⁡ ( V X ) ln ⁡ ( 2 )
where: N=number of cycles; DL,=detection limit for optical signal [moles/liter]; X=initial number of DNA molecules; V=volume containing DNA molecules [liters]; AN=Avagadro's number [6.023×1023 molecules/mole]. From Equation E1 it is clear that N, the number of cycles until detection, decreases as V, the partitioned fluid volume, decreases.

The system 100 reduces the duration of each temperature cycle by effectively increasing the concentration of reactants by enclosing them in picoliter type volumes. Since reaction rates depend on the concentration of the reactants, the efficiency of a partitioned fluid volume or droplet should be higher than in an ordinary vessel (such as a test tube) where the reactant quantity (DNA quantity) is extremely low. It is estimated that through the reduction in the number of cycles and the reduction in the time required for each cycles that the FPDD technique can reduce the detection time by an order of magnitude as compared to bulk solution DNA detection techniques.

The system 100 facilitates removal of interference from competing DNA templates. Given the extremely small volumes involved with Fluid-Partitioned DNA Detection (FPDD), it is possible to isolate a single template of the target DNA in a given partitioned volume or microdroplet. For example, the formation of 2000 partitioned fluid volumes or microdroplets (each with a volume of 5×10′9 liters) made by dividing a bulk solution of 10 microliters containing 200 DNA molecules, would result in one DNA molecule per microdroplet on average. This makes it possible to amplify only one template in mixtures containing many kinds of templates without interference. This is extremely important in processing of real world aerosol samples containing complex mixtures of DNA from many sources, and has direct application in screening of cDNA libraries. The system 100 facilitates removal of interference from competing DNA templates. Given the extremely small volumes involved with Fluid-Partitioned DNA Detection (FPDD), it is possible to isolate a single template of the target DNA in a given partitioned volume or microdroplet. For example, the formation of 2000 partitioned fluid volumes or microdroplets (each with a volume of 5×10′9 liters) made by dividing a bulk solution of 10 microliters containing 2000 DNA molecules, would result in one DNA molecule per microdroplet on average. This makes it possible to amplify only one template in mixtures containing many kinds of templates without interference. This is extremely important in processing of real world aerosol samples containing complex mixtures of DNA from many sources, and has direct application in screening of cDNA libraries.

Referring now to FIG. 2, a flow diagram of another embodiment of a system constructed in accordance with the present invention is illustrated. The system is designated generally by the reference numeral 200. The flow diagram illustrating system 200 shows block 201 “partitioning” the sample, block 202 performing “PCR” on the sample, and block 203 “detection and analysis.” The system 200 provides a method and apparatus for performing extremely rapid nucleic acid amplification and detection. The system 200 provides an apparatus for nucleic acid amplification of a sample comprising means for partitioning the sample into partitioned sections, means for performing PCR on the partitioned sections, and means for detection and analysis of the partitioned sections. The system 200 also provides a method of nucleic acid amplification of a sample comprising the steps of partitioning the sample into partitioned sections, subjecting the partitioned sections to PCR, and detecting and analyzing the partitioned sections of the sample.

In block 201 a chemical reagent and an input sample are “partitioned” into a large number of microdroplets or other forms of fluid partitions prior to amplification. The system 200 achieves a reduction in the total number of cycles by limiting the dilution of the optically generated signal (e.g., fluorescence or absorption). The formation of partitioned fluid volumes of the DNA-containing solution effectively isolates the fluid volumes which contain the target DNA from the fluid volumes that do not contain the target DNA. Therefore, the dilution of the optical signal is largely eliminated, allowing much earlier detection. This effect is directly related to the number of fluid partitions formed from the initial sample/reagent pool.

In block 202 selected portions of each nucleic acid sample are then amplified using polymerase chain reaction (PCR), with the product contained in each partitioned fluid volume. This results in much more concentrated amplification product, since the volume containing the reaction is so small. If a Taqman type detection approach is used, fluorescent dye molecules unquenched by the PCF amplification are also more concentrated, making possible earlier optical based detection. Since it is possible to contain very amounts of the starting target DNA in each partition fluid volume, inhibitory competition from near-neighbor DNA templates is less allowing screening of very dilute samples.

In block 203 partitioned portions of the sample are detected by monitoring for the calorimetric indicator (e.g., fluorescence or optical absorption) generated with each DNA template duplication sequence. The partitioned portions of the sample are optically probed to detect the colorimetric indicator which signals the presence of the target DNA. The partitioned portions of the sample can also be scanned optically to detect the colorimetric indicator signaling the presence of the target DNA. In one embodiment, fluorescence, generated by degradation of the dye/quencher pair on the primer, is detected using a confocal imaging system such as that employed in conventional flow cytometers. Scattering profiles from individual microdroplets, as in conventional flow cytometers, can be used to eliminate background signal from other particles. In block 203 partitioned portions of the sample are detected by monitoring for the colorimetric indicator (e.g., fluorescence or optical absorption) generated with each DNA template duplication sequence. The partitioned portions of the sample are optically probed to detect the colorimetric indicator which signals the presence of the target DNA. The partitioned portions of the sample can also be scanned optically to detect the colorimetric indicator signaling the presence of the target DNA. In one embodiment, fluorescence, generated by degradation of the dye/quencher pair on the primer, is detected using a confocal imaging system such as that employed in conventional flow cytometers. Scattering profiles from individual microdroplets, as in conventional flow cytometers, can be used to eliminate background signal from other particles.

The system 200 has application wherever current PCR-type systems exist, including medical, drug-discovery, biowarfare detection, and other related fields. Biowarfare detection applications include identifying, detecting, and monitoring bio-threat agents that contain nucleic acid signatures, such as spores, bacteria, etc. Biomedical applications include tracking, identifying, and monitoring outbreaks of infectious disease. The system 200 provides rapid, high throughput detection of biological pathogens (viruses, bacteria, DNA in biological fluids, blood, saliva, etc.) for medical applications. Forensic applications include rapid, high throughput detection of DNA in biological fluids for forensic purposes. Food and beverage safety applications include automated food testing for bacterial contamination.

Referring now to FIG. 3, a diagram of another embodiment of a system constructed in accordance with the present invention is illustrated. The system is designated generally by the reference numeral 300. The system 300 provides an instrument for performing Fluid-Partitioned DNA Detection (FPDD) with PCR based detection and amplification. The system 300 includes a partitioning section 301, a PCR section 302, and a detection and analysis section 303.

The partitioning section 301 includes a sample introduction unit 304 and a unit 305 where the sample and a PCR reagent are combined. The sample and a PCR reagent are injected through a small orifice 306. The injection of the sample through the small orifice 306 produces microdroplets 308.

The PCR section 302 includes a continuous tube 309 for circulating the microdroplets 308 and suspended in an immiscible carrier fluid 314. The microdroplets 308 suspended in an immiscible carrier fluid 314 are pumped through the continuous tube 309 by pump 311. The microdroplets 308 suspended in an immiscible carrier fluid 314 are cycled through heater 310 and cooler 315 to perform PCR.

The detection and analysis section 303 includes a blue laser 312 and a detector 313. The laser 312 is projected upon the droplets 308 as they pass through tube 308 between the laser 312 and the detector 313.

In the system 300, the DNA-containing solution is partitioned into many microdroplets 308 and suspended in an immiscible carrier fluid 314. The microdroplets 308 are formed by forcing the PCR mix (sample and reagent) through the small orifice or microjet 306. These microdroplets 308 are then captured in the immiscible fluid 314, such as mineral oil, and flowed past the heating element 310 and cooler 315. An optical signal (e.g., fluorescence or optical absorption), generated by degradation of the dye/quencher pair on the primer, is detected using a confocal imaging system such as that employed in conventional flow cytometers. Scattering profiles from individual microdroplets, as in conventional flow cytometers, can be used to eliminate background signal from other particles. Once exposed to multiple heating cycles, the microdroplets can be identified and probed for an optical signal at rates of several thousand per second.

The FPDD system achieves a reduction in the total number of cycles by limiting the dilution of the optically generated signal (e.g., fluorescence or absorption). The formation of partitioned fluid volumes of the DNA-containing solution effectively isolates the fluid volumes which contain the target DNA from the fluid volumes that do not contain the target DNA. Therefore, the dilution of the optical signal is largely eliminated, allowing much earlier detection. This effect is directly related to the number of fluid partitions formed from the initial sample/reagent pool. The effect of the number of fluid partitions on the number of cycles required for detection is described by the Equation E1 set out earlier.

The FPDD technique reduces the duration of each temperature cycle by effectively increasing the concentration of reactants by enclosing them in picoliter type volumes. Since reaction rates depend on the concentration of the reactants, the efficiency of a partitioned fluid volume or droplet should be higher than in an ordinary vessel (such as a test tube) where the reactant quantity (DNA quantity) is extremely low. It is estimated that through the reduction in the number of cycles and the reduction in the time required for each cycles that the FPDD technique can reduce the detection time by an order of magnitude as compared to bulk solution DNA detection techniques

The FPDD technique facilitates removal of interference from competing DNA templates. Given the extremely small volumes involved with FPDD, it is possible to isolate a single template of the target DNA in a given partitioned volume or microdroplet. For example, the formation of 2000 partitioned fluid volumes or microdroplets (each with a volume of 5×10−9 liters) made by dividing a bulk solution of 10 microliters containing 200 DNA molecules, would result in one DNA molecule per microdroplet on average. This makes it possible to amplify only one template in mixtures containing many kinds of templates without interference. This is extremely important in processing of real world aerosol samples containing complex mixtures of DNA from many sources, and has direct application in screening of cDNA libraries. The FPDD technique facilitates removal of interference from competing DNA templates. Given the extremely small volumes involved with FPDD, it is possible to isolate a single template of the target DNA in a given partitioned volume or microdroplet. For example, the formation of 2000 partitioned fluid volumes or microdroplets (each with a volume of 5×10−9 liters) made by dividing a bulk solution of 10 microliters containing containing 2000 DNA molecules, would result in one DNA molecule per microdroplet on average. This makes it possible to amplify only one template in mixtures containing many kinds of templates without interference. This is extremely important in processing of real world aerosol samples containing complex mixtures of DNA from many sources, and has direct application in screening of cDNA libraries.

With this new bioassay technique, each partitioned DNA-containing fluid volume contains the necessary biochemical constituents for selectively amplifying a specified portion of a sample DNA via polymerase chain reaction (PCR). The target DNA is detected by monitoring for the colorimetric indicator (e.g., fluorescence or optical absorption) generated with each DNA template duplication sequence.

The system 300 provides a fast, flexible and inexpensive high throughput, bioassay technology based on creation and suspension of microdroplets in an immiscible carrier stream. Each microdroplet contains the necessary biochemical constituents for selectively amplifying and fluorescently detecting a specified portion of a sample DNA via polymerase chain reaction (PCR). Once exposed to multiple heating cooling cycles, the microdroplets can be identified and probed for fluorescent signal at rates of several thousand per second.

Isolating the PCR reaction in such small (picoliter) volumes provides an order of magnitude reduction in overall detection time by:

    • (1) reducing the duration of each temperature cycle—the concentration of reactants increases by enclosing them in picoliter type volumes. Since reaction kinetics depend on the concentration of the reactant, the efficiency of a microdroplet should be higher than in an ordinary vessel (such a test tube) where the reactant quantity is infinitesimal
    • (2) reducing the total number of cycles—dilution of the fluorescently generated signal is largely eliminated in such a small volume, allowing much earlier detection. This effect is directly related to the number of microdroplets formed from the initial sample/reagent pool. Since PCR is an exponential process, for example, 1000 microdroplets would produce a signal 10 cycles faster than typical processing with bulk solutions.
    • (3) removing interference from competing DNA templates—given the extremely small volumes involved, it is possible to isolate a single template of the target DNA in a given microdroplet. A pL microdoplet filled with a 1 pM solution, for example, will be occupied by only one molecule on average. This makes it possible to amplify only one template in mixtures containing many kinds of templates without interference. This is extremely important in processing of real world aerosol samples containing complex mixtures of DNA from many sources, and has direct application in screening of precious cDNA libraries.

Referring now to FIG. 4, an illustration of another embodiment of a system constructed in accordance with the present invention is illustrated. The system is designated generally by the reference numeral 400. The system 300 provides system for nucleic acid amplification of a sample. The system 400 includes means for partitioning the sample into partitioned sections and means for performing PCR on the partitioned sections of the sample.

The sample is separated into immiscible slugs 406, 407, and 408. The immiscible slugs 406, 407, and 408 are formed through a system of microfluidics. Background information on microfluidics is contained in U.S. Pat. No. 5,876,187 for micropumps with fixed valves to Fred K. Forster et al., patented Mar. 2, 1999. As stated in U.S. Pat. No. 5,876,187, “Miniature pumps, hereafter referred to as micropumps, can be constructed using fabrication techniques adapted from those applied to integrated circuits. Such fabrication techniques are often referred to as micromachining. Micropumps are in great demand for environmental, biomedical, medical, biotechnical, printing, analytical instrumentation, and miniature cooling applications.” Microchannels 403, 404, and 405 are formed in substrates 401 and 402. The disclosures of U.S. Pat. Nos. 5,876,187 and 5,876,187 are incorporated herein by reference.

The immiscible slugs 406, 407, and 408 can be moved through the microchannels using magnetohydrodynamics. Background information on magnetohydrodynamics is contained in U.S. Pat. No. 6,146,103 for micromachined magnetohydrodynamic actuators and sensors to Abraham P. Lee and Asuncion V. Lemoff, patented Nov. 14, 2000. As stated in U.S. Pat. No. 6,146,103, “Microfluidics is the field for manipulating fluid samples and reagents in minute quantities, such as in micromachined channels, to enable handheld bioinstrumentation and diagnostic tools with quicker process speeds. The ultimate goal is to integrate pumping, valving, mixing, reaction, and detection on a chip for biotechnological, chemical, environmental, and health care applications. Most micropumps developed thus far have been complicated, both in fabrication and design, and often are difficult to reduce in size, negating many integrated fluidic applications. Most pumps have a moving component to indirectly pump the fluid, generating pulsatile flow instead of continuous flow. With moving parts involved, dead volume is often a serious problem, causing cross-contamination in biological sensitive processes. The present invention utilizes MHDs for microfluid propulsion and fluid sensing, the microfabrication methods for such a pump, and the integration of multiple pumps for a microfluidic system. MHDs is the application of Lorentz force law on fluids to propel or pump fluids. Under the Lorentz force law, charged particles moving in a uniform magnetic field feel a force perpendicular to both the motion and the magnetic field. It has thus been recognized that in the microscale, the MHD forces are substantial for propulsion of fluids through microchannels as actuators, such as a micropump, micromixer, or microvalve, or as sensors, such as a microflow meter, or viscosity meter. This advantageous scaling phenomenon also lends itself to micromachining by integrating microchannels with micro-electrodes.” The disclosure of U.S. Pat. No. 6,146,103 is incorporated herein by reference.

The means for performing PCR on the partitioned sections of the sample can be a system for alternately heating and cooling the immiscible slugs 406, 407, and 408. Alternatively, the means for performing PCR on the partitioned sections of the sample can be a system for alternately heating and cooling the immiscible slugs 406, 407, and 408 can be a system for moving the immiscible slugs 406, 407, and 408 through zones for heating and cooling. An example of such a system is shown in U.S. patent application No. 2002/0127152 published Sep. 12, 2002 for a convectively driven PCR thermal-cycling system described as follows: “A polymerase chain reaction system provides an upper temperature zone and a lower temperature zone in a fluid sample. Channels set up convection cells in the fluid sample and move the fluid sample repeatedly through the upper and lower temperature zone creating thermal cycling.” The disclosure of U.S. Patent Application No. 2002/0127152 is incorporated herein by reference.

In another embodiment of the invention, the DNA-containing solution is partitioned by adding a gelling agent to the solution to form cells of partitioned volumes of fluid separated by the gelling agent. Using this approach for fluid partitioning, the DNA-containing solution is gelled in a tube or as a very thin layer. For example, it can be in a thin layer between flat plates and the surface of the thin film can be optically probed spatially in directions parallel to the film surface to detect micro-regions in the film where the colorimetric indicator suggests the presence of the target DNA.

Another embodiment of the invention is to partition the DNA-containing solution as microdroplets in an immiscible fluid where the droplets are arranged in a two-dimensional array such that the array of microdroplets can be optically probed to detect the colorimetric indicator which signals the presence of the target DNA. In this approach a solid hydrophobic substrate supports the microdroplets. For example, in small indentations, and the immiscible “partitioning” fluid is less dense than the aqueous DNA-containing solution.

In another embodiment of the invention the DNA-containing solution is partitioned using mechanical means. For example, the DNA-containing solution can be partitioned into an array of capillaries, microtubes, or wells. In this approach, the micro vessels holding each partitioned fluid volume can be scanned optically to detect the colorimetric indicator signaling the presence of the target DNA.

Referring now to FIGS. 5A, 5B, and 5C example representations of the mechanical partitioning approach for DNA detection using fluid partitioning are shown. In FIG. 5A a line of capillaries or micro-tubes 501 are used for partitioning and holding the DNA containing solution. In FIG. 5B an array 502 of capillaries or micro-tubes are used for partitioning the DNA-containing solution. In FIG. 5C a microwells or micro-vessels unit 503 is used for partitioning and holding the DNA-containing solution.

While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.

Claims

1. An apparatus for nucleic acid amplification of a sample, comprising:

means for partitioning said sample into partitioned sections, wherein said means for partitioning said sample into partitioned sections comprises an injection orifice, and
means for performing PCR on said partitioned sections of said sample.

2. The apparatus for nucleic acid amplification of a sample of claim 1 wherein said injection orifice is an injection orifice that produces microdroplets.

3. The apparatus for nucleic acid amplification of a sample of claim 1 wherein said injection orifice is an injection orifice that injects said sample and a PCR reagent.

4. The apparatus for nucleic acid amplification of a sample of claim 1 wherein said means for performing PCR on said partitioned sections of said sample comprises a continuous tube for circulating said partitioned sections of said sample through a heater to perform PCR.

5. The apparatus for nucleic acid amplification of a sample of claim 1 wherein said means for performing PCR on said partitioned sections of said sample comprises a continuous tube for circulating said partitioned sections of said sample through a heater and cooler to perform PCR.

6. The apparatus for nucleic acid amplification of a sample of claim 1 wherein said means for performing PCR on said partitioned sections of said sample comprises a pump, a continuous tube, and a heater.

7. The apparatus for nucleic acid amplification of a sample of claim 1 including means for detection and analysis of said partitioned sections of said sample comprising a laser and a detector.

8. The apparatus for nucleic acid amplification of a sample of claim 1 including means for detection and analysis of said partitioned sections of said sample comprising a blue laser and a detector.

9. The apparatus for nucleic acid amplification of a sample of claim 1 wherein said means for partitioning said sample into partitioned sections comprises means for separating said sample into immiscible slugs.

10. A method of nucleic acid amplification of a sample, comprising the steps of:

partitioning said sample into partitioned sections, wherein said step of partitioning said sample into partitioned sections comprises flowing said sample through an injection orifice, and
subjecting said partitioned sections of said sample to PCR.

11. A method of nucleic acid amplification of a sample, the method comprising the steps

a. providing an aqueous solution, wherein the aqueous solution comprises components for performing nucleic acid amplification and an input sample comprising a plurality of nucleic acids;
b. providing an immiscible partitioning fluid;
c. providing a solid substrate, wherein the solid substrate comprises a two-dimensional array of small indentations;
d. contacting the aqueous solution with the immiscible partitioning fluid on the solid substrate, wherein the immiscible partitioning fluid is less dense than the aqueous solution, wherein the solid substrate is configured such that the contacting the aqueous solution with the immiscible partitioning fluid partitions the input sample comprising the plurality of nucleic acids into one or more microdroplets, and wherein the one or more microdroplets are further partitioned into and held by the two-dimensional array of small indentations; and
e. performing nucleic acid amplification of the one or more microdroplets held by the two-dimensional array of small indentations.

12. The method of claim 11, wherein the solid substrate is hydrophobic.

13. The method of claim 11, wherein the nucleic acid amplification step comprises alternately heating and cooling the solid substrate.

14. The method of claim 11, wherein the nucleic acids comprise a target DNA.

15. The method of claim 12, wherein the one or more microdroplets contain, on average, a single template of the target DNA, and wherein the single template is amplified within the one or more microdroplets.

16. The method of claim 11, wherein the components for performing nucleic acid amplification comprise one or more polymerase chain reaction (PCR) reagents.

17. The method of claim 11, wherein the method further comprises detecting one or more products of the nucleic acid amplification.

18. The method of claim 17, wherein the detecting comprises optically detecting.

19. The method of claim 18, wherein the optically detecting comprises confocal imaging.

20. The method of claim 18, wherein the optically detecting comprises laser excitation.

21. The method of claim 18, wherein the optically detecting comprises fluorescent detection.

22. The method of claim 18, wherein the optically detecting comprises detecting a colorimetric indicator.

23. The method of claim 18, wherein the optically detecting comprises signaling the presence of a target nucleic acid.

24. The method of claim 11, wherein the nucleic acid amplification comprises multiple heating and cooling cycles.

25. The method of claim 24, wherein the number of cycles is sufficient to detect products of the nucleic acid amplification.

26. The method of claim 11, wherein the one or more microdroplets have a volume of about 5×10−9 to 10−12 liters.

Referenced Cited
U.S. Patent Documents
3575220 April 1971 Davis et al.
4283262 August 11, 1981 Cormier et al.
4801529 January 31, 1989 Perlman
4948961 August 14, 1990 Hillman et al.
5091652 February 25, 1992 Mathies et al.
5176203 January 5, 1993 Larzul
5270183 December 14, 1993 Corbett et al.
5376252 December 27, 1994 Ekstrom et al.
5422277 June 6, 1995 Connelly et al.
5585069 December 17, 1996 Zanzucchi et al.
5587128 December 24, 1996 Wilding et al.
5602756 February 11, 1997 Atwood et al.
5736314 April 7, 1998 Hayes et al.
5827480 October 27, 1998 Haff et al.
5842787 December 1, 1998 Kopf-Sill et al.
5846735 December 8, 1998 Stapleton
5856174 January 5, 1999 Lipshutz et al.
5858187 January 12, 1999 Ramsey et al.
5912945 June 15, 1999 Da Silva et al.
5928907 July 27, 1999 Woudenberg et al.
5945334 August 31, 1999 Besemer et al.
5972716 October 26, 1999 Ragusa et al.
6033880 March 7, 2000 Haff et al.
6057149 May 2, 2000 Burns et al.
6126899 October 3, 2000 Woudenberg et al.
6130098 October 10, 2000 Handique et al.
6143496 November 7, 2000 Brown et al.
6146103 November 14, 2000 Lee et al.
6156181 December 5, 2000 Parce et al.
6174673 January 16, 2001 Short et al.
6175669 January 16, 2001 Colston et al.
6176609 January 23, 2001 Cleveland et al.
6177479 January 23, 2001 Nakajima et al.
6221654 April 24, 2001 Quake et al.
6281254 August 28, 2001 Nakajima et al.
6337740 January 8, 2002 Parce
6344325 February 5, 2002 Quake et al.
6357907 March 19, 2002 Cleveland et al.
6384915 May 7, 2002 Everett et al.
6391559 May 21, 2002 Brown et al.
6403338 June 11, 2002 Knapp et al.
6429025 August 6, 2002 Parce et al.
6440706 August 27, 2002 Vogelstein et al.
6466713 October 15, 2002 Everett et al.
6479299 November 12, 2002 Parce et al.
6488895 December 3, 2002 Kennedy
6494104 December 17, 2002 Kawakita et al.
6509085 January 21, 2003 Kennedy
6521427 February 18, 2003 Evans
6522407 February 18, 2003 Everett et al.
6524456 February 25, 2003 Ramsey et al.
6540895 April 1, 2003 Spence et al.
6551841 April 22, 2003 Wilding et al.
6558916 May 6, 2003 Veerapandian et al.
6575188 June 10, 2003 Parunak
6602472 August 5, 2003 Zimmermann et al.
6637463 October 28, 2003 Lei et al.
6660367 December 9, 2003 Yang et al.
6663619 December 16, 2003 Odrich et al.
6664044 December 16, 2003 Sato
6670153 December 30, 2003 Stern
6767706 July 27, 2004 Quake et al.
6773566 August 10, 2004 Shenderov
6833242 December 21, 2004 Quake et al.
6900021 May 31, 2005 Harrison et al.
6905885 June 14, 2005 Colston et al.
6960437 November 1, 2005 Enzelberger et al.
6964846 November 15, 2005 Shuber
7010391 March 7, 2006 Handique et al.
7041481 May 9, 2006 Anderson et al.
7052244 May 30, 2006 Fouillet et al.
7081336 July 25, 2006 Bao et al.
7091048 August 15, 2006 Parce et al.
7094379 August 22, 2006 Fouillet et al.
7118910 October 10, 2006 Unger et al.
7129091 October 31, 2006 Ismagilov et al.
7188731 March 13, 2007 Brown et al.
7192557 March 20, 2007 Wu et al.
7198897 April 3, 2007 Wangh et al.
7238268 July 3, 2007 Ramsey et al.
7244567 July 17, 2007 Chen et al.
7252943 August 7, 2007 Griffiths et al.
7268167 September 11, 2007 Higuchi et al.
7268179 September 11, 2007 Brown
7270786 September 18, 2007 Parunak et al.
7279146 October 9, 2007 Nassef et al.
7294503 November 13, 2007 Quake et al.
7312085 December 25, 2007 Chou et al.
7323305 January 29, 2008 Leamon et al.
7368233 May 6, 2008 Shuber et al.
7459315 December 2, 2008 Brown
7514210 April 7, 2009 Holliger
7595195 September 29, 2009 Lee et al.
7622280 November 24, 2009 Holliger et al.
7682565 March 23, 2010 Linton et al.
RE41780 September 28, 2010 Anderson et al.
7833708 November 16, 2010 Enzelberger et al.
7842457 November 30, 2010 Berka et al.
7927797 April 19, 2011 Nobile et al.
7972778 July 5, 2011 Brown et al.
8067159 November 29, 2011 Brown et al.
RE43365 May 8, 2012 Anderson et al.
8257925 September 4, 2012 Brown et al.
8278071 October 2, 2012 Brown et al.
8304193 November 6, 2012 Ismagilov et al.
RE45539 June 2, 2015 Anderson et al.
9127310 September 8, 2015 Larson et al.
RE46322 February 28, 2017 Anderson et al.
9968933 May 15, 2018 Ismagilov et al.
RE47080 October 9, 2018 Anderson
20010000752 May 3, 2001 Franzen
20010039014 November 8, 2001 Bass et al.
20010041357 November 15, 2001 Fouillet et al.
20010046701 November 29, 2001 Schulte et al.
20020021866 February 21, 2002 Everett et al.
20020058332 May 16, 2002 Quake et al.
20020093655 July 18, 2002 Everett et al.
20020119459 August 29, 2002 Griffiths
20020141903 October 3, 2002 Parunak et al.
20020164820 November 7, 2002 Brown
20030003441 January 2, 2003 Colston et al.
20030027244 February 6, 2003 Colston et al.
20030032172 February 13, 2003 Colston, Jr. et al.
20030170698 September 11, 2003 Gascoyne et al.
20030204130 October 30, 2003 Colston, Jr. et al.
20040038385 February 26, 2004 Langlois et al.
20040074849 April 22, 2004 Brown et al.
20040171055 September 2, 2004 Brown
20040180346 September 16, 2004 Anderson et al.
20040185484 September 23, 2004 Costa et al.
20040208792 October 21, 2004 Linton et al.
20040224325 November 11, 2004 Knapp et al.
20050032240 February 10, 2005 Lee et al.
20050042639 February 24, 2005 Knapp et al.
20050042684 February 24, 2005 Aehle et al.
20050064460 March 24, 2005 Holliger et al.
20050079510 April 14, 2005 Berka et al.
20050221279 October 6, 2005 Carter et al.
20050221373 October 6, 2005 Enzelberger et al.
20050227264 October 13, 2005 Nobile et al.
20050239192 October 27, 2005 Nasarabadi et al.
20060057599 March 16, 2006 Dzenitis et al.
20060094108 May 4, 2006 Yoder et al.
20060172336 August 3, 2006 Higuchi et al.
20060263264 November 23, 2006 Bohm et al.
20070227890 October 4, 2007 Ramsey et al.
20080138815 June 12, 2008 Brown et al.
20080145923 June 19, 2008 Hahn et al.
20080153091 June 26, 2008 Brown et al.
20080160525 July 3, 2008 Brown et al.
20080161420 July 3, 2008 Shuber
20080166793 July 10, 2008 Beer et al.
20080169184 July 17, 2008 Brown et al.
20080171324 July 17, 2008 Brown et al.
20080171325 July 17, 2008 Brown et al.
20080171326 July 17, 2008 Brown et al.
20080171327 July 17, 2008 Brown et al.
20080171380 July 17, 2008 Brown et al.
20080171382 July 17, 2008 Brown et al.
20080213766 September 4, 2008 Brown et al.
20090035838 February 5, 2009 Quake et al.
20090325236 December 31, 2009 Griffiths et al.
Foreign Patent Documents
2004-225691 October 2004 AU
0672834 September 1995 EP
0843589 May 1998 EP
1053790 November 2000 EP
1522582 July 2007 EP
WO 1984/02000 May 1984 WO
WO 1992/001812 February 1992 WO
WO 1994/005414 March 1994 WO
WO 1998/41869 September 1998 WO
WO 1998/047003 October 1998 WO
WO 2001/07159 February 2001 WO
WO 2001/57263 August 2001 WO
2002/22869 March 2002 WO
WO 2002/023163 March 2002 WO
WO 02/081490 October 2002 WO
WO 2002/081490 October 2002 WO
WO 2002/081729 October 2002 WO
WO 2003/016558 February 2003 WO
WO 2003/072258 September 2003 WO
WO 2003/106678 December 2003 WO
WO 2005/010145 February 2005 WO
WO 2005/075683 August 2005 WO
WO 2008/109878 September 2008 WO
Other references
  • Nisisako et al, “Droplet Formation in a microchannel network,” Lab Chip, 2002, 2, pp. 24-26 (Year: 2002).
  • 3M Fluorinert™ Electronic Liquid FC-3283, 3M product information, 2001.
  • Abdelgawad, M. et al., “All-terrain droplet actuation,” Lab on a Chip, 2008, pp. 672-677, vol. 8.
  • ABIL® EM 90, Goldschmidt Personal Care product literature, 2003, 7 pages.
  • Adang, A.E., et al., “The Contribution of Combinatorial Chemistry to Lead Generation: An Interim Analysis,” Current Medical Chemistry, 2001, pp. 985-998, vol. 8.
  • Anarbaev, R., et al., “Klenow fragment and DNA polymerase α-primase fromserva calf thymus in water-in-oil microemulsions,” Biochimica et Biophysica Acta, 1998, pp. 315-324, vol. 1384.
  • Baroud, C., et al., “Thermocapillary Valve for Droplet Production and Sorting,” Physical Review E, 2007, pp. 046302-1 to 046302-5, vol. 75.
  • Beer, N., et al., “On-Chip Single-Copy Real-Time Reverse-Transcription PCR in Isolated Picoliter Droplets,” Anal. Chem., 2008, pp. 1854-1858, vol. 80, No. 6.
  • Beer, N. et al., On-Chip, Real-Time, Single-Copy Polymerase Chain Reaction in Picoliter Droplets, Anal. Chem., 2007, pp. 8471-8475, vol. 79, No. 22.
  • Bransky, A., et al., “A Microfluidic Droplet Generator Based on a Piezoelectric Actuator,” Lab Chip, 2009, pp. 516-520, vol. 9.
  • Carroll, N., et al., “Droplet-Based Microfluidics for Emulsion and Solvent Evaporation Synthesis of Monodisperse Mesoporous Silica Microspheres,” Langmuir, 2008, pp. 658-661, vol. 24.
  • Chabert, M., et al., “Droplet fusion by alternating current (AC) field electrocoalescence in microchannels,” Electrophoresis, 2005, pp. 3706-3715, vol. 26.
  • Chen, D. L., et al., “Using Three-Phase Flow of Immiscible Liquids to Prevent Coalescence of Droplets in Microfluidic Channels: Criteria to Identify the Third Liquid and Validation with Protein Crystallization,” Langmuir, 2007, pp., 2255-2260, vol. 23.
  • Clausell-Tormos, J., et al., “Droplet-Based Microfluidic Platforms for the Encapsulation and Screening and Mammalian Cells and Multicellular Organisms,” Chemistry and Biology, 2008, pp. 427-437, vol. 15.
  • Diehl, F., et al., “Digital quantification of mutant DNA in cancer patients,” Current Opinion in Oncology, 2007, pp. 36-42, vol. 19.
  • Diekema, D.J., et al., “Look before You Leap: Active Surveillance for Multidrug-Resistant Organisms,” Healthcare Epidemiology, 2007, pp. 1101-1107, vol. 44.
  • Dressman, D., et al., “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations,”PNAS, 2003, pp. 8817-8822, vol. 100, No. 15.
  • Fan, J.B., et al., “Highly parallel genomic assays,” Nature Reviews, Genetics, 2006, pp. 632-644, vol. 7.
  • Fidalgo, L. M., et al., “Coupling Microdroplet Microreactors with Mass Spectrometry: Reading the Contents of Single Droplets Online,” Angew. Chem. Int. Ed., 2009, pp. 3665-3668, vol. 48.
  • Halloran, P.J., Letter to John H. Lee, Assistant Laboratory Counsel, Lawrence Livermore National Laboratory, re U.S. Appl. No. 12/118,418, filed Jun. 4, 2010, 5 pages.
  • Heyries, K.A., et al., “Megapixel digital PCR,” Nature Methods, 2011, 5 Pages.
  • Higuchi, R., et al., “Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions,” Bio/Technology, 1993, pp. 1026-1030, vol. 11.
  • Jarvius, J., et al., “Digital quantification using amplified single-molecule detection,” Nature Methods, 2006, pp. 725-727, vol. 3, No. 9; includes supplementary information from www.nature.com website.
  • Kalinina, O., et al., “Nanoliter scale PCR with TaqMan detection,” Nucleic Acids Res., 1997, pp. 1999-2004, vol. 25, No. 10.
  • Katsura, S., et al., “Indirect Micromanipulation of Single Molecules in Water-In-Oil Emulsion,” 2001, Electrophoresis, pp. 289-293, vol. 22.
  • Kiss, M. M., et al., “High-Throughput Quantitative Polymerase Chain Reaction in Picoliter Droplets,” Anal. Chem., DOI: 10.1021/ac801276c, Nov. 17, 2008 <http://pubs.acs.org>.
  • Kojima, T., et al., “PCR amplification from single DNA molecules on magnetic beads in emulsion: application for high-throughput screening of transcription factor targets,” Nucleic Acids Res., 2005, vol. 33, No. 17, e150.
  • Kopp, M., et al., “Chemical Amplification: Continuous-Flow PCR on a Chip,” Science, 1998, pp. 1046-1048, vol. 280, [Online] [Retrieved on Sep. 22, 2009] Retrieved from the internet URL <http://www.sciencemag.org/cgi/content/ful1/280/5366/1046.
  • Kumaresan, P., et al., “High-Throughput Single Copy DNA Amplification and Cell Analysis in Engineered Nanoliter Droplets,” Anal. Chem., DOI: 10.1021/ac800327d, Apr. 15, 2008 <http://pubs.acs.org>, plus supporting information.
  • Leamon, J. H., et al., “Overview: methods and applications for droplet compartmentalization of biology,” Nature Methods, 2006, pp. 541-543, vol. 3, No. 7.
  • Lin, Y. H., et al., “Droplet Formation Utilizing Controllable Moving-Wall Structures for Double-Emulsion Applications,” Journal of Microelectromechanical Systems, 2008, pp. 573-581, vol. 17 No. 3.
  • Link, D. R., et al., “Electric Control of Droplets in Microfluidic Devices,” Angew. Chem. Int. Ed., 2006, pp. 2556-2560, vol. 45.
  • Liu, K., et al., “Droplet-based synthetic method using microflow focusing and droplet fusion,” Microfluid Nano fluid, 2007, pp. 239-243, vol. 3.
  • Lo, Y. M., et al., “Digital PCR for the molecular detection of fetal chromosomal aneuploidy,” PNAS, 2007, pp. 13116-13121, vol. 104, No. 32.
  • Margulies, M., et al., “Genome sequencing in microfabricated high-density picloitre reactors,” Nature, 2005, pp. 376-380, vol. 437; includes supplementary information from www.nature.com website.
  • Margulies, M., et al., Supplementary figures from JM Rothberg, Nature, May 2005, 12 Pages.
  • Margulies, M., et al., Supplementary methods from JM Rothbert, Nature, May 2005, 34 Pages.
  • Musyanovych, A., et al., “Miniemulsion Droplets as Single Molecule Nanoreactors for Polymerase Chain Reaction,” Biomacromolecules, 2005, pp. 1824-1828, vol. 6.
  • Nagai, H., et al., “Development of a Microchamber Array for Picoliter PCR,” Anal. Chem., 2001, pp. 1043-1047, vol. 73, No. 5.
  • Nakano, M., et al., Single-molecule PCR using water-in-oil emulsion, Journal of Biotechnology, 2003, pp. 117-124, vol. 102.
  • Nisisako, T., et al., “Formation of Droplets Using Branch Channels in a Microfluidic Circuit,” SICE Aug. 5-7, 2002, pp. 1262-1264.
  • Pamme, N., “Continuous flow separations in microfluidic devices,” Lab Chip, 2007, pp. 1644-1659, vol. 7.
  • Pohl, G., et al., “Principle and applications of digital PCR,” Expert Rev. Mol. Diagn., 2004, pp. 41-47, vol. 4, No. 1.
  • Price, C. P., “Regular review: Point of care testing,” BMJ, 2001, pp. 1285-1288, vol. 322.
  • Roach, L. S., et al., “Controlling Nonspecific Protein Adsorption in a Plug-Based Microfluidic System by Controlling Interfacial Chemistry Using Fluorous-Phase Surfactants,” Anal. Chem., 2005, pp. 785-796, vol. 77, No. 3.
  • Rutledge, R. G., et al., “Mathematics of quantitative kinetic PCR and the application of standard curves,” Nucleic Acids Res., 2003, p. e93, vol. 31, No. 16.
  • Rutledge, R. G., “Sigmoidal curve-fitting redefines quantitative real-time PCR with the prospective of developing automated high-throughput applications,” Nucleic Acids Res., 2004, p. e178, vol. 32, No. 22.
  • Schneegass, I., et al., “Miniaturized Flow-through PCR with Different Template Types in a Silicon Chip Thermocycler,” Lab on a Chip, 2001, pp. 42-49, vol. 1.
  • U.S. Appl. No. 60/443,471, filed Jan. 29, 2003, 68 Pages.
  • Vogelstein, B., et al., “Digital PCR,” PNAS, 1999, pp. 9236-9241, vol. 96.
  • Williams, R., et al., “Amplification of complex gene libraries by emulsion PCR,” Nature Methods, 2006, pp. 545-550, vol. 3, No. 7.
  • Zhang, T., et al., “Behavioral Modeling and Performance Evaluation of Microelectrofluidics-Based PCR Systems Using SystemC,” IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems, 2004, pp. 843-858, vol. 23, No. 6.
  • Zhang, C., et al., “Miniaturized PCR chips for nucleic acid amplification and analysis: latest advances and future trends,” Nucleic Acids Res., 2007, pp. 4223-4237, vol. 35.
  • Zhao, Y., et al., Microparticle Concentration and Separation by Traveling-Wave Dielectrophoresis (twDEP) for Digital Microfluidics, Journal of Microelectromechanical Systems, 2007, pp. 1472-1481, vol. 16, No. 6.
  • Zhelev, T., et al., “Heat Integration in Micro-Fluidic Devices,” 16th European Symposium on Computer Aided Process Engineering and 9th International Symposium on Process Systems Engineering, 2006, pp. 1863-1868.
  • USDC, District of Massachusetts, Civil Case No. 1:19CV11587, Docket Report, retrieved from PACER, Apr. 7, 2020.
  • USDC, District of Massachusetts, Civil Case No. 1:19CV11587, Docket No. 1, Complaint Against Stilla Technologies, Inc., and Exhibits 1-6, filed by Bio-Rad Laboratories, Inc. and The University of Chicago, Jul. 22, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 19, Answer to Complaint with Jury Demand and Exhibits 1-5, filed by Stilla Technologies, Inc., Sep. 23, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 21, First Amended Answer to Complaint with Jury Demand and Counterclaim against Bio-Rad Laboratories and the University of Chicago, with Exhibits 1-9, filed by Stilla Technologies, Inc., Oct. 10, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 25, Amended Complaint Against Stilla Technologies, Inc., filed by Bio-Rad Laboratories, Inc., The University of Chicago, Lawrence Livermore National Security, LLC and President and Fellows of Harvard College, with Exhibits 1-10, Oct. 11, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 39, Answer to Amended Complaint and Counterclaim Against Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College, and The University of Chicago, with Exhibits 1-20, filed by Stilla Technologies, Nov. 19, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 43, Stipulated Protective Order with Exhibits 1-2, Dec. 10, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 44, Stipulated E-Discovery Order with Exhibit 1, Dec. 10, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 54, Motion to Strike and Dismiss Defendants' Affirmative Defenses and Counterclaims by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College and The University of Chicago, Dec. 17, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 55, Memorandum in Support of Motion to Strike and Dismiss Defendants' Affirmative Defenses and Counterclaims with Exhibits 1-16, by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College and The University of Chicago, Dec. 17, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 60, Motion to Consolidate Cases by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College and The University of Chicago, Dec. 30, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 61, Memorandum in Support of Motion to Consolidate Cases by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College and The University of Chicago, Dec. 30, 2019.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 64, Opposition to Motion to Strike and Dismiss Defendants' Affirmative Defenses and Counterclaims filed by Stilla Technologies, Inc., Jan. 7, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 68, Order Denying Motion to Strike and Dismiss Defendants' Affirmative Defenses and Counterclaims, Jan. 8, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 73, Plaintiffs' Unopposed Motion for Leave to Amend Preliminary Patent-Related Disclosures by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College and the University of Chicago, Jan. 10, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 74, Order Granting Plaintiffs' Unopposed Motion for Leave to Amend Preliminary Patent-Related Disclosures by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College and The University of Chicago, Jan. 13, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 75, Opposition to Motion to Consolidate Cases filed by Stilla Technologies, Jan. 13, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 76, Opposition to Motion to Consolidate Cases filed by Genomics, Inc., Jan. 13, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 77, Declaration re Opposition to Motion to Consolidate Cases filed by Genomics, Inc., Jan. 13, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 78, Order Granting Motion to Consolidate Cases, Jan. 14, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 82, Document Disclosure and Attachments 1-4, by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College and The University of Chicago, Jan. 14, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 83, Plaintiffs' Answer to Counterclaim of Stilla Technologies, filed by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security, LLC, President and Fellows of Harvard College and The University of Chicago, Jan. 22, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 85, Order Granting Protective Order as Modified with Exhibits 1-2, Feb. 11, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 89, Joint Claim Construction and Prehearing Statement by Bio-Rad Laboratories, Inc., Mar. 12, 2020.
  • USDC District of Massachusetts Civil Case No. 1:19CV11587, Docket No. 90, Joint Claim Construction and Prehearing Statement by Bio-Rad Laboratories, Inc., President and Fellows of Harvard College and The University of Chicago, Mar. 12, 2020.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 111, Declaration of Luc Bousse Regarding Claim Construction with Exhibits A-BB, filed Jul. 20, 2020, 1106 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 108, Plaintiffs' Opening Claim Constrcution Brief, filed Jul. 20, 2020, 27 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 109, Declaration of Justin L. Constant in Support of Plaintiffs' Opening Claim construction Brief, filed Jul. 20, 2020, 2 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 110, Defendants' Opeining Claim Construction Brief, filed Jul. 20, 2020, 25 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 112, Motion for Leave to File Amended Claim Constrction Statement, filed Jul. 20, 2020, 3 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 120, Amended Claim Construction Statement, filed Jul. 29, 2020, 7 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Docket Report, retrieved from PACER, Sep. 21, 2020, 28 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 134, Defendants' Responsive Claim Construction Brief, filed Aug. 20, 2020, 26 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 135, Plaintiffs' Responsive Claim Construction Brief, filed Aug. 20, 2020, 25 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 136, Declaration of Justin L Constant in Support of Bio-Rad's Claim Construction Brief, Filed Aug. 20, 2020, 2 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 139, Joint Statement of Counsel Regarding Markman Hearing, filed Aug. 26, 2020, 7 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 143, Plaintiffs' Markman Hearing Presentation, filed Sep. 10, 2020, 139 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 144, Claim Construction Presentation, filed Sep. 10, 2020, 84 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 150, Transcript of Markman Hearing held on Sep. 10, 2020, filed Sep. 22, 2020, 50 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Bio-Rad Laboratories, Inc. et al. v. Stilla Technologies Inc. et al., Docket 155, Claim Construction Memorandum and Order, filed Oct. 23, 2020, 42 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Docket Report, retrieved from PACER, Feb. 19, 2021, 33 pages.
  • Carl D. Meinhart Curriculum Vitae, May 2020.
  • Case No. IPR2021-00218, Docket Report, retrieved from DocketNavigator, Feb. 24, 2021, 4 pages.
  • Case No. IPR2021-00302, Docket Report, retrieved from DocketNavigator, Feb. 25, 2021, 2 pages.
  • Curcio et al., “Continuous Segmented-Flow Polymerase Chain Reaction for High-Throughput Miniaturized DNA Amplification,” Analytical Chemistry, 2003, 75(1):1-7.
  • He et al., “Capillary-based fully integrated and automated system for nanoliter polymerase chain reaction analysis directly from cheek cells,” Journal of Chromatography A, 2001, 924:271-284.
  • Katsura et al., “Indirect micromanipulation of single molecules in water-in-oil emulsion,” Electrophoresis, 2001, 22:289-293.
  • Kopp et al., “Chemical Amplification: Continuous-Flow PCR on a Chip,” Science, 1998, 280:1046-1048.
  • Lagally et al., “Monolithic integrated microfluidic DNA amplification and capillary electrophoresis analysis system,” Sensors and Actuators B, 2000, 63:138-146.
  • Litborn et al., “Synthesis and Analysis of Chemical Components in Nanoscale,” Micro Total Analysis Systems, 2000, 447-454.
  • Merriam-Webster's Collegiate Dictionary, Tenth Edition, 2002, p. 600.
  • Oxford Dictionary of Mechanical Engineering, 2013, p. 242.
  • Oxford Dictionary of Mechanical Engineering, 2013, p. 394.
  • Response to First Office Action in Ex Parte Reexamination of U.S. Pat. No. 8,304,193 filed Jun. 12, 2018.
  • Schneegass et al., “Flow-through polymerase chain reactions in chip thermocyclers,” Review in Molecular Biotechnology, 2001, 82:101-121.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 1, Complaint filed with Jury Demand against Dropworks, Inc.—filed by The University of Chicago, Bio-Rad Laboratories, Inc., filed Apr. 14, 2020, 474 pages.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 14, First Amended Complaint against Dropworks, Inc.—filed by The University of Chicago, Bio-Rad Laboratories, Inc., Lawrence Livermore National Security LLC, filed Jul. 6, 2020, 547 pages.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 15, Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) U.S. Pat. No. 8,304,193 B2; U.S. Pat. No. 9,127,310 B2; U.S. Pat. No. Re. 41,780 E; U.S. Pat. No. Re. 43,365 E, filed Jul. 6, 2020, 1 page.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 16, Answer to 14 Amended Complaint, with Jury Demand, and Counterclaims against Bio-Rad Laboratories, Inc., Lawrence Livermore National Security LLC, The University of Chicago, by Dropworks, Inc., filed Jul. 27, 2020, 26 pages.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 27, Second Amended Complaint against Dropworks, Inc.—filed by The University of Chicago, Lawrence Livermore National Security LLC, Bio-Rad Laboratories, Inc., President and Fellows of Harvard College, filed Aug. 12, 2020, 600 pages.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 28, Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) U.S. Pat. No. 8,304,193 B2; U.S. Pat. No. 9,127,310 B2; U.S. Pat. No. Re. 41,780 E; U.S. Pat. No. RE. 43,365 E; U.S. Pat. No. 9,056,289, filed Aug. 12, 2020, 1 page.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 3, Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) U.S. Pat. No. 8,304,193 B2; U.S. Pat. No. 9,127,310 B2, filed Apr. 14, 2020, 1 page.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 33, Answer to 27 Amended Complaint, with Jury Demand and Counterclaims against Bio-Rad Laboratories, Inc., Lawrence Livermore National Security LLC, President and Fellows of Harvard College, The University of Chicago, by Dropworks, Inc. filed Aug. 26, 2020, 33 pages.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 40, Answer to 33 Answer to Amended Complaint, and Counterclaims, by Bio-Rad Laboratories, Inc., Lawrence Livermore National Security LLC, President and Fellows of Harvard College, The University of Chicago, filed Sep. 16, 2020, 13 pages.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 44, Letter to the Honorable Richard G. Andrews from Jason J. Rawnsley regarding Petitions of inter partes review of U.S. Pat. No. 9,127,310 and U.S. Pat. No. Re. 41,780, filed Nov. 23, 2020, 167 pages.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Bio-Rad Laboratories, Inc. et al. v. Dropworks Inc., Docket 55, Letter to the Honorable Richard G. Andrews from Jason J. Rawnsley regarding Petition for inter partes review, filed Jan. 5, 2021, 72 pages.
  • USDC, District of Delaware, Civil Action No. 20-cv-506-RGA, Docket Report, retrieved from PACER, Feb. 24, 2021, 15 pages.
  • USPTO, U.S. Appl. No. 60/394,544, Ismagilov, “Device and Method for Pressure-Driven Plug Transport,” filed Jul. 8, 2002.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00218, Dropworks Inc. et al. v. Lawrence Livermore National Security LLC, Docket 1, Petition for Inter Partes Review of U.S. Pat. No. Re. 41,780, filed Nov. 18, 2020, 83 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00218, Dropworks Inc. et al. v. Lawrence Livermore National Security LLC, Docket 1009, Meinhart Decl Nov. 18, 2020, filed Nov. 18, 2020, 116 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00218, Dropworks Inc. et al. v. Lawrence Livermore National Security LLC Docket 1022, Petition for Inter Partes Review Case No. IPR2021-00100 Dropworks Inc. et al. v. The University of Chicago et al., filed Oct. 22, 2020, 87 pages.
  • USPTO, Patent Trial and Appeal Board, IPR Trial No. 2021-00302, Dropworks Inc. et al. v. Lawrence Livermore National Security LLC, Docket 3, Petition for Inter Partes Review of U.S. Pat. No. Re. 43,365, filed Dec. 8, 2020, 70 pages.
  • Woolley et al., “Functional Integration of PCR Amplification and Capillary Electrophoresis in a Microfabricated DNA Analysis Device,” Analytical Chemistry, 1996, 68(23):4081-4086.
  • Case No. 1:19cv11587, Docket Report, retrieved from LexisNexis, Jun. 4, 2021, 40 pages.
  • Case No. 1:20cv506, Docket Report, retrieved from LexisNexis, Jun. 4, 2021, 17 pages.
  • Case No. IPR2021-00218, Docket Report, retrieved from LexisNexis, Jun. 4, 2021, 18 pages.
  • Case No. IPR2021-00302, Docket Report, retrieved from LexisNexis, Jun. 4, 2021, 16 pages.
  • J. R. Burns, et al., “The intensification of rapid reactions in multiphase systems using slug flow in capillaries,” Lab on a Chip, 2001, 1:10-15.
  • Lagally, et al., “Single-Molecule DNA Amplification and Analysis in an Integrated Microfluidic Device,” Anal. Chern., 2001, 73(3):565-570.
  • M. A. Burns, et al., “Microfabricated structures for integrated DNA analysis,” Proc. Natl. Acad. Sci. USA, 1996, 93:5556-5561.
  • USDC, District of Delaware, Civil Action No. 1:15-cv-00152-RGA, Document 218, filed Sep. 1, 2017, 5 pages.
  • USDC, District of Delaware, Civil Action No. 1:20-cv-00506-RGA, Document 72, filed Mar. 8, 2021, 1 page.
  • USDC, District of Delaware, Civil Action No. 1:20-cv-00506-RGA, Document 74, filed Mar. 15, 2021, 173 pages.
  • USDC, District of Delaware, Civil Action No. 1:20-cv-00506-RGA, Document 77, filed Mar. 22, 2021, 44 pages.
  • USDC, District of Delaware, Civil Action No. 1:20-cv-00506-RGA, Document 80, filed Apr. 5, 2021, 16 pages.
  • USDC, District of Delaware, Civil Action No. 1:20-cv-00506-RGA, Document 85, filed Apr. 30, 2021, 809 pages.
  • USDC, District of Delaware, Civil Action No. 1:20-cv-00506-RGA, Document 86, filed Apr. 30, 2021, 816 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 166, filed Feb. 28, 2021, 12 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 167, filed Feb. 28, 2021, 292 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 172, filed Mar. 15, 2021, 38 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 180, filed Apr. 14, 2021, 442 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 184, filed Apr. 14, 2021, 65 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 187, filed Apr. 15, 2021, 16 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 188, filed Apr. 15, 2021, 22 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 189, filed Apr. 15, 2021, 364 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00218, “Email chain between Amal Moulik and Brian Anderson,” Document 2008, filed Mar. 2, 2021, 3 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00218, “Patent Owner's Pre-lnstitution Surreply,” Document 14, filed Apr. 14, 2021, 17 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00218, “Patent Owner's Preliminary Response to Petition tor Inter Partes Review of U.S. Patent RE41,780,” Document 11, filed Mar. 2, 2021, 71 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00218, “Record of Invention Draft,” Document 2017, filed Mar. 2, 2021, 15 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00218, “Trial Instituted Document,” Document 15, filed Jun. 1, 2021, 39 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00302, “Patent Owner's Pre-lnstitution Surreply,” Document 16, filed Apr. 14, 2021, 17 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00302, “Patent Owner's Preliminary Response to Petition for Inter Partes Review of U.S. Patent RE43,365,” Document 14, filed Mar. 17, 2021, 62 pages.
  • USPTO, Patent Trial and Appeal Board, Case No. IPR2021-00302, “Trial Instituted Document,” Document 17, filed Jun. 2, 2021, 41 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 192, filed Apr. 27, 2021, 126 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 193, filed Apr. 28, 2021, 37 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 194, filed May 5, 2021, 413 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 198, filed May 5, 2021, 64 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 200, filed May 5, 2021, 33 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 202, filed May 5, 2021, 37 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 204, filed May 5, 2021, 46 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 217, filed May 28, 2021, 62 pages.
  • USDC, District of Massachusetts, Civil Action No. 1:19-cv-11587-WGY, Document 225, filed May 28, 2021, 26 pages.
Patent History
Patent number: RE48704
Type: Grant
Filed: Aug 28, 2018
Date of Patent: Aug 24, 2021
Assignee: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (Livermore, CA)
Inventors: Brian L. Anderson (Lodi, CA), Bill W. Colston (San Ramon, CA), Christopher J. Elkin (Cranston, RI)
Primary Examiner: Alan D Diamond
Application Number: 16/115,187
Classifications
Current U.S. Class: Particle Count Or Volume Standard Or Control (e.g., Platelet Count Standards, Etc.) (436/10)
International Classification: C12Q 1/6806 (20180101); C12Q 1/6844 (20180101);